肝纤维化逆转的病理评估  

Pathological assessment of liver fibrosis regression

作　　者：王冰琼 孙亚朦[1] 尤红[1] 邵晨[2] 王泰龄[3] WANG Bingqiong SUN Yameng YOU Hong et al(Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China)

机构地区：[1]首都医科大学附属北京友谊医院肝病中心,国家消化系统疾病临床医学研究中心,北京100050 [2]首都医科大学附属北京佑安医院病理科,北京100069 [3]中日友好医院病理科,北京100039

出　　处：《临床肝胆病杂志》2017年第3期435-437,共3页Journal of Clinical Hepatology

摘　　要：肝纤维化是慢性肝脏疾病的共同病理结局,准确评估肝纤维化程度对明确疾病诊断、治疗决策、监测疗效及判断预后均有重要参考价值。目前已有多项临床研究证实,经过有效治疗肝纤维化/早期肝硬化是可以逆转的,如何正确评价肝纤维化逆转成为临床研究热点。肝活组织检查一直以来都是肝纤维化评价的金标准,因此其对纤维化逆转评价至关重要。从半定量、定量、定性评价3个方面回顾了现有肝纤维化病理分期标准在肝纤维化逆转中的临床应用进展,以提出更好的病理评价体系评估肝纤维化逆转。Hepatic fibrosis is the common pathological outcome of chronic hepatic diseases.An accurate assessment of fibrosis degree provides an important reference for a definite diagnosis of diseases,treatment decision-making,treatment outcome monitoring,and prognostic evaluation.At present,many clinical studies have proven that regression of hepatic fibrosis and early-stage liver cirrhosis can be achieved by effective treatment,and a correct evaluation of fibrosis regression has become a hot topic in clinical research.Liver biopsy has long been regarded as the gold standard for the assessment of hepatic fibrosis,and thus it plays an important role in the evaluation of fibrosis regression.This article reviews the clinical application of current pathological staging systems in the evaluation of fibrosis regression from the perspectives of semi-quantitative scoring system,quantitative approach,and qualitative approach,in order to propose a better pathological evaluation system for the assessment of fibrosis regression.

关 键 词：肝硬化 逆转 病理过程 

分 类 号：R575.2[医药卫生—消化系统]